Gentilly, August 24th, 2018 We are proud to announce to you that FDA officially approved DIACOMIT for the US, on August 20th, 2018. The FDA’s approval of DIACOMIT is a major milestone for BIOCODEX. It recognizes our R&D excellence in developing therapies for Dravet syndrome and brings a new treatment option to young patients in the USA. DIACOMIT is the result of BIOCODEX’s own research and has been the subject of substantial investment. Our research work, along with the pre-clinical and clinical studies carried out in close collaboration with teams of university experts from around the world, have enabled us to obtain approval in Europe, Japan, Canada and, as of now, in the United States. After several years of “special access program” of DIACOMIT in USA, we are particularly pleased to be able to provide American health professionals and patients suffering from this rare and serious disease with a drug which may improve their quality of life, as well as that of their families.  Our efforts will not stop there. We are continuing our research on DIACOMIT (Stiripentol) in order to do everything in our power to improve treatment for children and adults suffering from pharmaco-resistant epilepsy. Press release